Clinical trials: Streptococcus Pneumoniae Infections
Pneumococcal Infections
Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
The purpose of this study is to assess the safety, tolerability, and immunogenicity of a single dose of different formulations of V114 (V114-A and V114-B) and Prevnar 13® (pneumococcal 13-valent conjugate vaccine) in adult…
- Trial name
- NCT02547649
- Testing
- V114-A, V114-B, Prevnar 13®
- Volunteers
- 690 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Streptococcal
Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of a booster dose of pneumococcal vaccines (GSK 2189242A) in young adults.
- Trial name
- NCT00896064
- Testing
- Pneumococcal vaccine GSK2189242A (formulation 1), Pneumococcal vaccine GSK2189242A (formulation 2)
- Where
- Belgium
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infection, ANCA-associated Vasculitis
Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis
Descriptive study of the residual anti-pneumococcal immunity in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) who have previously gone through pneumococcal immunization.
- Trial name
- NCT02463539
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pneumococcal Disease
Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination
This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination
- Trial name
- NCT03835975
- Testing
- 13vPnC, PPSV23, 20vPnC
- Where
- 42 sites in United States, Sweden
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections, Respiratory Syncytial Virus (RSV) Infection
In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)
The NoseSpn-Elderly study aims at characterizing the immune response in the upper respiratory tract in adults aged 60 and over diagnosed with a pneumonia due to a Streptococcus pneumoniae (Spn) infection.
- Conditions
- Pneumococcal Infections, Respiratory Syncytial Virus (RSV) Infection, Influenza Infection
- Trial name
- NoseSpnElderly (NCT06998251)
- Where
- Switzerland
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Streptococcus Pneumoniae Infections
Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine
This clinical study aims to evaluate the mutual influence of combined administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine in the target population
- Trial name
- NCT06817187
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed), Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)
- Where
- China
- Volunteers
- 1,110 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pneumococcal Disease
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit…
- Trial name
- NCT07365826
- Testing
- 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok)
- Where
- 25 sites in United States
- Volunteers
- 1,390 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Invasive Pneumococcal Infection
Evaluation of Vaccination for Streptococcus Pneumoniae in Adults With an Episode of Invasive Pneumococcal Infection.
Respiratory tract infections are among the leading causes of death worldwide and many of these infections are preventable through vaccination.
- Trial name
- pVax (NCT06334185)
- Volunteers
- 320 people
- Sponsor
- Azienda Ospedaliera di Lecco
Pulmonary Disease, Chronic Obstructive, Pneumonia, Bacterial
Modulation of Steroid Immunosuppression by Alveolar Efferocytosis
The long-term goals of this study are (a) to understand the biological underpinnings for the increased incidence of community-acquired pneumonia in patients with chronic obstructive pulmonary disease (COPD) who are treated with…
- Trial name
- NCT03034642
- Testing
- Bronchoscopy with bilateral bronchoalveolar lavages
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VA Ann Arbor Healthcare System
Pneumococcal Infection
A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax
Streptococcus pneumoniae is a type of bacteria that can cause infections of the ears, sinuses or lungs. It can also cause more serious infections of the blood or brain.
- Trial name
- NCT02572635
- Testing
- PnuBioVax
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- ImmunoBiology Limited
HIV Infections, Pneumococcal Infections
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 18 years of age or older who have been previously immunized with at least one…
- Trial name
- NCT00963235
- Testing
- 13-valent pneumococcal conjugate vaccine, Blood draw
- Where
- 15 sites in United States
- Volunteers
- 331 people
- Sponsor
- Pfizer
Otitis Media, Pneumococcal Infections
Efficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Vaccine Serotypes
This was a randomized, double-blinded multicenter cohort study of Finnish children aged 2 to 24 months. The study was designed to evaluate the efficacy of two 7-valent pneumococcal conjugate vaccines (PncCRM and PncOMPC)…
- Trial name
- NCT00378417
- Testing
- 7-valent pneumococcal-CRM197 conjugate vaccine, 7-valent pneumococcal-OMPC conjugate vaccine
- Where
- 5 sites in Finland
- Volunteers
- 3,075 people, healthy volunteers welcome
- Sponsor
- Finnish Institute for Health and Welfare
Community-acquired Pneumonia
Description of Pneumococcal Pneumonia
Statement of the problem: Overprescription of antibiotics raises important public health issues because of the emergence of multiresistant bacteria by selection pressure.
- Trial name
- PneumoCAP (NCT03322670)
- Testing
- Signs of CAP and a positive chest X-Ray, Patients directly hospitalized, Control patients
- Where
- France
- Volunteers
- 412 people
- Sponsor
- CNGE Conseil
Pneumonia
A Study To Examine Serologic Response In Hospitalized Patients Receiving Polyvalent Pneumococcal Vaccine
Investigators in the Division of Infectious Diseases and the Division of Hospital Medicine of The George Washington University Medical Center are carrying out a study to determine if hospitalized patients receiving the polyvalent…
- Trial name
- NCT00955851
- Testing
- Pre and post vaccination titers
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- George Washington University
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)
This study is designed to evaluate the safety, tolerability, and immunogenicity of two different lots of V114 in healthy infants 6 to 12 weeks (>=42 days to <=90 days) of age.
- Trial name
- NCT02987972
- Testing
- V114 Lot 1, V114 Lot 2, Prevnar 13™
- Where
- 49 sites in United States, Canada and 4 more
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Upper and Lower Respiratory Tract Infections (RTIs)
Prevention of Respiratory Infections and MAnagement Among Children (PRIMAKid)
The PRIMAKid trial is a general practice based double-blind randomized placebo-controlled trial on the effectiveness and costs of combined influenza and pneumococcal vaccination in pre-school children with recurrent respiratory…
- Trial name
- NCT00161122
- Testing
- trivalent inactivated influenza vaccine, combined heptavalent pneumococcal conjugate vaccine and trivalent inactivated influenza vaccine
- Where
- Netherlands
- Volunteers
- 660 people
- Sponsor
- UMC Utrecht
Infections, Meningococcal
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with…
- Trial name
- NCT03621670
- Testing
- Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 1,196 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Allogeneic Haematopoietic Stem Cell Transplantation
Vaccination of Children Following Allogeneic Stem Cell Transplantation
The purpose of this study is to determine the immunogenicity and tolerability of the DTaP-IPV-HBV/Hib combination vaccine Infanrix hexa and the heptavalent pneumococcal conjugate vaccine Prevenar in pediatric recipients of…
- Trial name
- NCT00169728
- Testing
- DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa, heptavalent pneumococcal conjugate vaccine, Prevenar
- Where
- 11 sites in Germany
- Volunteers
- 53 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Pneumococcal Infections
Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V114 administered subcutaneously or intramuscularly in healthy Japanese infants (3 months of age).
- Trial name
- NCT03848065
- Testing
- V114, Pneumococcal 13-valent Conjugate Vaccine (PCV13), Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)
- Where
- 14 sites in Japan
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Influenza, Human, Pneumococcal Infections
Influenza Vaccine and Pneumococcal Vaccine
Previous studies have demonstrated the immunogenicity and safety of the co-administration of the trivalent inactivated influenza vaccine (IIV3) with the polysaccharide pneumococcal vaccine (PPV) or pneumococcal conjugate vaccine…
- Trial name
- NCT02582047
- Testing
- Influenza vaccination with PPV23, Influenza vaccination with PCV13
- Where
- 2 sites in South Korea
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital